INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 138 filers reported holding INFINITY PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 1.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $35,000 | +16.7% | 22,299 | 0.0% | 0.00% | – |
| Q2 2016 | $30,000 | -74.6% | 22,299 | 0.0% | 0.00% | – |
| Q1 2016 | $118,000 | -34.8% | 22,299 | -3.5% | 0.00% | – |
| Q4 2015 | $181,000 | -14.6% | 23,119 | -8.0% | 0.00% | – |
| Q3 2015 | $212,000 | -22.9% | 25,119 | 0.0% | 0.00% | – |
| Q2 2015 | $275,000 | -14.9% | 25,119 | +8.7% | 0.00% | – |
| Q1 2015 | $323,000 | -13.6% | 23,119 | +4.5% | 0.00% | – |
| Q4 2014 | $374,000 | +41.1% | 22,119 | +12.2% | 0.00% | – |
| Q3 2014 | $265,000 | +5.6% | 19,719 | 0.0% | 0.00% | – |
| Q2 2014 | $251,000 | -92.8% | 19,719 | -93.3% | 0.00% | -100.0% |
| Q1 2014 | $3,481,000 | -25.0% | 292,725 | -12.9% | 0.00% | -20.0% |
| Q4 2013 | $4,643,000 | -18.8% | 336,219 | +2.6% | 0.01% | -28.6% |
| Q3 2013 | $5,717,000 | +48.6% | 327,619 | +38.4% | 0.01% | +40.0% |
| Q2 2013 | $3,847,000 | – | 236,719 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |